Prognostic impact of postoperative serum CA 19-9 levels in patients with resectable pancreatic cancer

Annals of Surgical Oncology

Volumn 19, Issue 2, 2012, Pages 636-641

  Hata, Shojiro ^a   Sakamoto, Yoshihiro ^a   Yamamoto, Yusuke ^a   Nara, Satoshi ^a   Esaki, Minoru ^a   Shimada, Kazuaki ^a   Kosuge, Tomoo ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL EVALUATION; CONTROLLED STUDY; FEMALE; HUMAN; INVASIVE CARCINOMA; LIVER CANCER; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; MICROSCOPY; MULTIVARIATE ANALYSIS; PANCREAS CANCER; PANCREAS RESECTION; PERITONEUM CANCER; POSTOPERATIVE PERIOD; PREOPERATIVE EVALUATION; PROTEIN BLOOD LEVEL; UNIVARIATE ANALYSIS;

ADULT; AGED; AGED, 80 AND OVER; CA-19-9 ANTIGEN; CARCINOMA, PANCREATIC DUCTAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PANCREATIC NEOPLASMS; POSTOPERATIVE CARE; PREOPERATIVE CARE; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84860420700     PISSN: 10689265     EISSN: 15344681     Source Type: Journal    
DOI: 10.1245/s10434-011-2020-9     Document Type: Article

References (18)

1. SC Mayo DF Austin BC Sheppard M Mori DK Shipley KG Billingsley 2010 Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: a population-based analysis Cancer. 116 2932 2940 20336787 10.1002/cncr.25082
2. FW Nugent K Stuart 2010 Adjuvant and neoadjuvant therapy in curable pancreatic cancer Surg Clin North Am. 90 323 329 20362789 10.1016/j.suc.2009.12. 010 1:STN:280:DC%2BC3c3jsVSgtQ%3D%3D
3. MM Corsini RC Miller MG Haddock, et al. 2008 Adjuvant radiotherapy and chemotherapy for pancreatic carcinoma: the Mayo Clinic experience (1975-2005) J Clin Oncol. 26 3511 3516 18640932 10.1200/JCO.2007.15.8782
4. K Shimada T Sano Y Sakamoto, et al. 2006 Clinical implications of combined portal vein resection as a palliative procedure in patients undergoing pancreaticoduodenectomy for pancreatic head carcinoma Ann Surg Oncol. 13 1569 1578 17009145 10.1245/s10434-006-9143-4
5. K Shimada Y Sakamoto T Sano T Kosuge 2006 Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail Surgery. 139 288 295 16546491 10.1016/j.surg.2005.08.004
6. CP Raut JF Tseng CC Sun, et al. 2007 Impact of resection status on pattern of failure and survival after pancreaticoduodenectomy for pancreatic adenocarcinoma Ann Surg. 246 52 60 17592291 10.1097/01.sla.0000259391.84304.2b
7. MF Brennan MW Kattan D Klimstra K Conlon 2004 Prognostic nomogram for patients undergoing resection for adenocarcinoma of the pancreas Ann Surg. 240 293 298 15273554 10.1097/01.sla.0000133125.85489.07
8. AC Berger IM Meszoely EA Ross, et al. 2004 Undetectable preoperative levels of serum CA 19-9 correlate with improved survival for patients with resectable pancreatic adenocarcinoma Ann Surg Oncol. 11 644 649 15197014 10.1245/ASO.2004.11.025
9. CM Kang JY Kim GH Choi, et al. 2007 The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer J Surg Res. 140 31 35 17418869 10.1016/j.jss.2006.10.007 1:CAS:528:DC%2BD2sXkvFOqsrs%3D
10. AC Berger M Garcia Jr JP Hoffman, et al. 2008 Postresection CA 19-9 predicts overall survival in patients with pancreatic cancer treated with adjuvant chemoradiation: a prospective validation by RTOG 9704 J Clin Oncol. 26 5918 5922 19029412 10.1200/JCO.2008.18.6288
11. TJ Kinsella Y Seo J Willis, et al. 2008 The impact of resection margin status and postoperative CA 19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer Am J Clin Oncol. 31 446 453 18838880 10.1097/COC.0b013e318168f6c4 1:CAS:528:DC%2BD1cXhtF2ktbfE
12. CR Ferrone DM Finkelstein SP Thayer, et al. 2006 Perioperative CA 19-9 levels can predict stage and survival in patients with resectable pancreatic adenocarcinoma J Clin Oncol. 4 2897 2902 10.1200/JCO.2005.05.3934
13. N Kondo Y Murakami K Uemura, et al. 2010 Prognostic impact of perioperative CA 19-9 levels in patients with resectable pancreatic cancer Ann Surg Oncol. 17 2321 2329 20336387 10.1245/s10434-010-1033-0
14. F Motoi T Rikiyama Y Katayose, et al. 2011 Retrospective evaluation of the influence of postoperative tumor marker status on survival and patterns of recurrence after surgery for pancreatic cancer based on RECIST guidelines Ann Surg Oncol 18 2 371 379 20842460 10.1245/s10434-010-1311-x
15. RC Montgomery JP Hoffman LB Riley A Rogatko JA Ridge BL Eisenberg 1997 Prediction of recurrence and survival by post-resection CA 19-9 values in patients with adenocarcinoma of the pancreas Ann Surg Oncol. 4 551 556 9367020 10.1007/BF02305535 1:STN:280:DyaK1c%2Fjtlyruw%3D%3D
16. Y Sakamoto K Shimada M Esaki, et al. 2007 Wrapping the stump of the gastroduodenal artery using the falciform ligament during pancreaticoduodenectomy J Am Coll Surg. 204 334 336 17254940 10.1016/j.jamcollsurg.2006.11.015
17. H Ueno T Kosuge Y Matsuyama, et al. 2009 A randomised phase III trial comparing gemcitabine with surgery-only in patients with resected pancreatic cancer: Japanese Study Group of Adjuvant Therapy for Pancreatic Cancer Br J Cancer. 101 908 915 19690548 10.1038/sj.bjc.6605256 1:CAS:528:DC%2BD1MXhtV2qsrjN
18. M Rapellino P Piantino F Pecchio, et al. 1994 Disappearance curves of tumor markers after radical surgery Int J Biol Markers. 9 33 37 8051433 1:STN:280:DyaK2czisl2ktA%3D%3D